All in one News Portal

Malaysia in talks to acquire Merck’s COVID-19 drugs

KUALA LUMPUR, Oct 2 (Reuters) – Malaysia is in talks to acquire an experimental antiviral capsule developed by Merck & Co (MRK.N) for COVID-19 remedy, the well being minister stated on Saturday.

Health Minister Khairy Jamaluddin stated in a tweet that he has began negotiations to acquire the brand new medication, referring to a Reuters story on Friday that the capsule developed by Merck might halve the possibilities of dying or being hospitalised for these most vulnerable to contracting extreme COVID-19.

“As we transition to living with COVID, we will be adding new, innovative treatment options to our arsenal in addition to vaccines,” he stated.

Merck and accomplice Ridgeback Biotherapeutics are planning to hunt U.S. emergency use authorisation for the capsule as quickly as potential and to make regulatory functions globally.

The capsule molnupiravir, designed to introduce errors into the genetic code of the virus, could be the primary oral antiviral treatment for COVID-19.

Current remedy choices embody Gilead Sciences Inc’s (GILD.O) infused antiviral remdesivir and generic steroid dexamethasone, each of that are typically solely given as soon as a affected person has already been hospitalised.

There was not quick response to a request to make clear if the ministry’s negotiations additionally included Gilead Sciences or Pfizer which is creating an antiviral capsule with Swiss drugmaker Roche Holding AG (ROG.S).

Reporting by Liz Lee; Editing by Michael Perry

People wearing protective masks cross a street outside a shopping mall, amid the coronavirus disease (COVID-19) outbreak in Kuala Lumpur, Malaysia, September 6, 2021. REUTERS/Lim Huey Teng